Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPEDE-PKD metformin versus placebo in ADPKD
ISRCTN12436830Phase 3Recruiting
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of metformin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Started Nov 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on ISRCTN12436830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12436830.